Pozen enrolling for Phase III study of heart drug
Pozen
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
CHAPEL HILL, N.C. — Pozen Inc. (NASDAQ: POZN) said Friday that it has begun enrolling 1,000 patients across the country for two Phase III studies for its experimental drug for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
The compound, PA32540, is a fixed-dose combination of 325 mg of enteric-coated aspirin and 40 mg of immediate-release omeprazole.
The two trials will operate under a special protocol assessment that Pozen and the federal Food and Drug Administration set up, Pozen said. The studies will involve over 100 sites, enrolling approximately 500 patients per study.
“We believe that PA32540 could address the needs of certain patients with cardiovascular disease,” said Dr. John Fort, Pozen's chief medical officer.
Copyright 2010 Local Tech Wire. All rights reserved.
Featured
Hot Off The Wire
- Hot Off the Wire – Man convicted in first economic espionage case; iPhone market share grows; Electronic Arts shares falter after revenue forecast; Phone company wants to charge Google
- FairPoint looks to cut debt by two thirds with bankruptcy plan
- Wake Tech lands $555,680 grant for STEM education program
E-mail Preferences
The Skinny
- Gears of War 3 coming? EA discloses Epic game for 2011
- Japan’s Nagoya University seeks to bridge East, West with Nu Tech showcase
- E-mail services provider iContact investigating a hack attack
- Cyberespionage? Cyberslueths disclose Lenovo’s 2010 ‘roadmap’
- Tech recovery is at hand, analysts tells N.C. IT execs
- Believe it - Triangle region lands record $1.9B in business projects
- Epic Games’ heroes take their guns to a new world – ‘Lost Planet 2’
- IPO rewards: Motricity CEO gets a $75,000 raise in new contract
- IT recession over? Spending will rebound, analysis firm says
- Google vs. the Dragon – War over words could ignite into flames